Clinical trials: Antivirals/HIV
Herpes Simplex, HIV Infections
SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir
To evaluate the safety and tolerance of topically applied SP-303T in AIDS patients. To observe the effect of this drug on herpes simplex virus lesions in patients who have failed to heal in response to oral or intravenous…
- Trial name
- NCT00002310
- Testing
- Crofelemer
- Where
- 4 sites in United States
- Sponsor
- Shaman Pharmaceuticals
AIDS Virus, Disorder of Immune Reconstitution
Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection
The goal of this clinical trial is to explore the effect of mesenchymal stem cell therapy on immune non-responder patients. The main questions it aims to answer are: 1.
- Trial name
- NCT05872659
- Testing
- normal saline, Mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
HIV-1
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen…
- Trial name
- NCT00799864
- Testing
- Rilpivirine, Zidovudine, Abacavir
- Where
- 17 sites in United States, India and 6 more
- Volunteers
- 54 people
- Sponsor
- Janssen Sciences Ireland UC
Antivirals/HIV
Drug Interaction Study
The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)
- Trial name
- NCT00646776
- Testing
- Rifabutin, Rifabutin + Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure
The primary objective was to determine the mean change in HIV viral load from baseline to Week 4 compared with placebo after 4 weeks of treatment in highly experienced HIV-infected patients.
- Trial name
- NCT02232581
- Testing
- Alovudine - low, Alovudine - medium, Alovudine - high
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Herpes Simplex, HIV Infections
Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS
The purpose of this study is to see if cidofovir gel (Forvade) is safe and effective in treating herpes simplex in patients with AIDS who do not respond to acyclovir.
- Trial name
- NCT00002181
- Testing
- Cidofovir
- Where
- 15 sites in United States
- Sponsor
- Gilead Sciences
HIV Infections
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
- Trial name
- NCT00036634
- Testing
- Tenofovir DF, Tenofovir alafenamide
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Influenza
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment…
- Trial name
- PO206 (NCT00979251)
- Testing
- Oseltamivir Phosphate, ADS-8902
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 2 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
HIV Infections
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients…
- Trial name
- NCT00561925
- Testing
- nevirapine IR, nevirapine XR
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 1,068 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir ) when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients with advanced HIV disease.
- Trial name
- NCT00002115
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
HIV Infections
The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients
To assess the effects of two doses of synthetic peptide construction 3 ( SPC3 ) on HIV-1 plasma levels (as measured by RNA PCR Amplicor) and on lymphocyte subsets in patients with initial viral load above 10,000 copies/ml.
- Trial name
- NCT00002363
- Testing
- Peptide Construction 3, Synthetic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia Research Laboratories
Human Immunodeficiency Virus, Ischemic Heart Disease
Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment
The purpose of this study is to evaluate the effect of Omacor 4g/day on blood lipid parameters and on the function and stiffness of blood vessels in HIV infected patients on Antiretroviral Therapy (HAART)
- Trial name
- NCT00296153
- Testing
- Omega-3-acid ethyl esters 90
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Pronova BioPharma
HIV Infections
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on…
- Trial name
- NCT00000628
- Testing
- L-697,661, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
DDI HV (ATV - Merck)
The purpose of this study is to to assess the effect of ATV 300 mg BID on the PK of raltegravir 400 mg BID, to assess the effect of raltegravir 400 mg BID on the PK of ATV 300 mg BID, and to assess the ECG effects of ATV 300 mg…
- Trial name
- NCT00518297
- Testing
- Raltegravir, Atazanavir, Atazanavir + Raltegravir
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.
- Trial name
- NCT00009061
- Testing
- Ritonavir, Abacavir sulfate, Nelfinavir mesylate
- Where
- 37 sites in United States
- Volunteers
- 624 people
- Sponsor
- Glaxo Wellcome
HIV Infections
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients
To study the safety, tolerance, and pharmacokinetics of a single dose of bis-POM PMEA (adefovir dipivoxil) when administered by the oral route in patients with HIV infection.
- Trial name
- NCT00002128
- Testing
- Adefovir dipivoxil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Gilead Sciences
HIV Infections
The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients
To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a daily basis for 2 weeks to HIV-infected patients.
- Trial name
- NCT00002346
- Testing
- Adefovir dipivoxil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
HIV Infections
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine).
- Trial name
- NCT00002240
- Testing
- Atazanavir, Nelfinavir mesylate, Stavudine
- Where
- 17 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin
This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy.
- Trial name
- NCT00001989
- Testing
- Trichosanthin, Zidovudine
- Where
- 8 sites in United States
- Sponsor
- Genelabs Technologies
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer